Corticotropin-Releasing Factor Receptor 1 Antagonist Alters Regional Activation and Effective Connectivity in an Emotional–Arousal Circuit during Expectation of Abdominal Pain

Alterations in corticotropin-releasing factor (CRF) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology. We aimed to (1) determine the effect of the selective CRF receptor 1 antagonist (CRF1) GW876008 relative to placebo, on regional activation and effective connectivity of a stress-related emotional–arousal circuit during expectation of abdominal pain using functional magnetic resonance imaging in human subjects with a diagnosis of IBS and healthy controls (HCs), and (2) examine GW876008 effects on state–trait anxiety and hypothalamic–pituitary–adrenal (HPA) axis response. Although there were no drug-related effects on peripheral HPA activity, significant central effects were observed in brain regions associated with the stress response. Effective connectivity analysis showed drug-induced normalizations between key regions of the emotional–arousal circuit in patients. During pain expectation, orally administered GW876008 relative to placebo produced significant blood oxygen level-dependent (BOLD) signal reductions in the amygdala, hippocampus, insula, anterior cingulate, and orbitomedial prefrontal cortices across groups. Patients showed significantly greater BOLD responses in the left locus coeruleus and hypothalamus after placebo compared with HCs, and BOLD signal decreases in the left hypothalamus after drug. The inhibitory effects of GW876008 in the hypothalamus in patients were moderated by anxiety; patients having average and high levels of state anxiety showed drug-related BOLD decreases. GW876008 represents a novel tool for elucidating the neuronal mechanisms and circuitry underlying hyperactivation of CRF/CRF1 signaling and its role in IBS pathophysiology. The unique state anxiety effects observed suggest a potential pathway for therapeutic benefit of CRF1 receptor antagonism for patients with stress-sensitive disorders.

[1]  M. Forsting,et al.  Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. , 2010, Gastroenterology.

[2]  Kirsten Tillisch,et al.  Regional gray matter density changes in brains of patients with irritable bowel syndrome. , 2010, Gastroenterology.

[3]  Rita J. Valentino,et al.  Sex Differences in Corticotropin-Releasing Factor Receptor Signaling and Trafficking: Potential Role in Female Vulnerability to Stress-Related Psychopathology , 2010, Molecular Psychiatry.

[4]  T. Delmonte,et al.  Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder , 2010, Depression and anxiety.

[5]  K. Davis,et al.  Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. , 2010, Gastroenterology.

[6]  G. Koob,et al.  Progress in corticotropin-releasing factor-1 antagonist development. , 2010, Drug discovery today.

[7]  E. V. Bockstaele,et al.  The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse , 2010, Brain Research.

[8]  Paul S. Morgan,et al.  In vivo mapping of the human locus coeruleus , 2009, NeuroImage.

[9]  Y. Taché,et al.  A role for corticotropin-releasing factor in functional gastrointestinal disorders , 2009, Current gastroenterology reports.

[10]  K. Holroyd,et al.  Moderation and mediation in the psychological and drug treatment of chronic tension-type headache: The role of disorder severity and psychiatric comorbidity , 2009, PAIN®.

[11]  D. Ffytche,et al.  Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder , 2009, Schizophrenia Research.

[12]  A. Zinsmeister,et al.  Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[13]  M. Forsting,et al.  Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study , 2009, Gut.

[14]  P. Baldi,et al.  Dysregulation of the hypothalamic‐pituitary‐adrenal (HPA) axis in irritable bowel syndrome , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[15]  Thomas Weiss,et al.  Dynamic activation of the anterior cingulate cortex during anticipatory anxiety , 2009, NeuroImage.

[16]  Steven Mark Miller,et al.  Apoptotic cell death of human interstitial cells of Cajal , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[17]  A. Capelli,et al.  Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. , 2008, Journal of medicinal chemistry.

[18]  M. C. Bushnell,et al.  Increased gray matter density in young women with chronic vulvar pain , 2008, PAIN.

[19]  M. Craske,et al.  Increased Acoustic Startle Responses in IBS Patients During Abdominal and Nonabdominal Threat , 2008, Psychosomatic medicine.

[20]  Jennifer S. Labus,et al.  Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: A network analysis , 2008, NeuroImage.

[21]  Q. Aziz,et al.  Brain imaging of visceral functions in healthy volunteers and IBS patients. , 2008, Journal of psychosomatic research.

[22]  J. Bueller,et al.  Reduced Brainstem Inhibition during Anticipated Pelvic Visceral Pain Correlates with Enhanced Brain Response to the Visceral Stimulus in Women with Irritable Bowel Syndrome , 2008, The Journal of Neuroscience.

[23]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[24]  B. Greenwood-Van Meerveld,et al.  Corticotropin‐releasing factor receptor 1‐deficient mice show decreased anxiety and colonic sensitivity , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[25]  Danielle S. Bassett,et al.  A validated network of effective amygdala connectivity , 2007, NeuroImage.

[26]  R Jones,et al.  Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.

[27]  K. G. J8reskoC,et al.  Simultaneous Factor Analysis in Several Populations , 2007 .

[28]  S. Fukudo.  Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation , 2007, Journal of Gastroenterology.

[29]  Y. Taché,et al.  CRF1 receptors as a therapeutic target for irritable bowel syndrome. , 2006, Current pharmaceutical design.

[30]  Y. Taché,et al.  The CRF1 receptor antagonist, NBI-35965, abolished the activation of locus coeruleus neurons induced by colorectal distension and intracisternal CRF in rats , 2005, Brain Research.

[31]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[32]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[33]  H. Houshyar,et al.  The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats , 2005, Psychopharmacology.

[34]  M. Hongo,et al.  Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome , 2004, Gut.

[35]  W. Vale,et al.  CRF and CRF receptors: role in stress responsivity and other behaviors. , 2004, Annual review of pharmacology and toxicology.

[36]  Florian Holsboer,et al.  Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. , 2003, Journal of psychiatric research.

[37]  Y. Taché,et al.  A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats , 2003, Brain Research.

[38]  R. Hauger,et al.  The CRF peptide family and their receptors: yet more partners discovered. , 2002, Trends in pharmacological sciences.

[39]  L. Takahashi.  Role of CRF1 and CRF2 receptors in fear and anxiety , 2001, Neuroscience & Biobehavioral Reviews.

[40]  J. Gore,et al.  Activation of the left amygdala to a cognitive representation of fear , 2001, Nature Neuroscience.

[41]  M. Raichle,et al.  Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Mayer,et al.  The neurobiology of stress and gastrointestinal disease , 2000, Gut.

[43]  T. Baram,et al.  Immunocytochemical distribution of corticotropin‐releasing hormone receptor type‐1 (CRF1)‐like immunoreactivity in the mouse brain: Light microscopy analysis using an antibody directed against the C‐terminus , 2000, The Journal of comparative neurology.

[44]  Robin C. Spiller,et al.  Rome II: the Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus , 2000 .

[45]  I. Wilkinson,et al.  Introduction to functional magnetic resonance imaging , 1999 .

[46]  B. Naliboff,et al.  Symptom differences in moderate to severe IBS patients based on predominant bowel habit , 1999, American Journal of Gastroenterology.

[47]  T. Insel,et al.  Autoradiographic and in situ hybridization localization of corticotropin‐releasing factor 1 and 2 receptors in nonhuman primate brain , 1999, The Journal of comparative neurology.

[48]  R. Miselis,et al.  Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions. , 1999, Trends in pharmacological sciences.

[49]  S. Small,et al.  AN INTRODUCTION TO FUNCTIONAL MAGNETIC RESONANCE IMAGING , 1999 .

[50]  M. Sugai,et al.  Effect of the Growth Rate of Pseudomonas aeruginosa Biofilms on the Susceptibility to Antimicrobial Agents: β-Lactams and Fluoroquinolones , 1999, Chemotherapy.

[51]  C. Nemeroff,et al.  The role of corticotropin-releasing factor in depression and anxiety disorders. , 1999, The Journal of endocrinology.

[52]  J. Spiess,et al.  Characterization of native corticotropin‐releasing factor receptor type 1 (cRFR1) in the rat and mouse central nervous system , 1998, Journal of neuroscience research.

[53]  M. Hongo,et al.  Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome , 1998, Gut.

[54]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[55]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[56]  Anne W. Schmidt,et al.  CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Fullerton,et al.  Effects of the corticotropin‐releasing factor (CRF) on rectal afferent nerves in humans , 1996, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[58]  F. Gonzalez-Lima,et al.  Structural equation modeling and its application to network analysis in functional brain imaging , 1994 .

[59]  Craig W. Berridge,et al.  Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? , 1990, Brain Research Reviews.

[60]  J. Davidson,et al.  The corticotropin-releasing hormone test in patients with posttraumatic stress disorder , 1989, Biological Psychiatry.

[61]  D. Watson,et al.  Development and validation of brief measures of positive and negative affect: the PANAS scales. , 1988, Journal of personality and social psychology.

[62]  S. Foote,et al.  Corticotropin-releasing hormone increases tonic but not sensory-evoked activity of noradrenergic locus coeruleus neurons in unanesthetized rats , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[63]  R. Hauger,et al.  Corticotropin‐releasing Factor Receptors: Distribution and Regulation in Brain, Pituitary, and Peripheral Tissues , 1987, Annals of the New York Academy of Sciences.

[64]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[65]  S. Foote,et al.  Corticotropin-releasing factor disrupts sensory responses of brain noradrenergic neurons. , 1987, Neuroendocrinology.

[66]  D. Jacobowitz,et al.  Distribution of corticotropin-releasing factor receptors in primate brain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Foote,et al.  Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus , 1983, Brain Research.

[68]  C. Spielberger.  Manual for the State-Trait Anxiety Inventory (STAI) (Form Y , 1983 .

[69]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. , 1982, Science.

[70]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[71]  W. Hall,et al.  On “Ratio scales of sensory and affective verbal pain descriptors” , 1981, Pain.

[72]  Ronald Dubner,et al.  Ratio scales of sensory and affective verbal pain descriptors , 1978, Pain.

[73]  K. Jöreskog.  Simultaneous factor analysis in several populations , 1971 .

[74]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .